Skip to main content

For Health Care Providers

During times of limited availability of therapeutic mediations, it is essential that all prescribers apply ethical principles in determining eligibility of these medications. Medications should only be prescribed in bonified clinician-patient relationships. Additional information on ethical principles during scarce resource allocations can be obtained through MDHHS.

What Is Antiviral Medication?

Antiviral medication is a treatment that kills a virus or suppresses its ability to replicate and, hence, inhibits its capability to multiply and reproduce. Vaccinations remain the best way to protect a person from COVID, and are a preventative measure to reduce severity of illness and risk of hospitalization or, even, death. Antivirals are prescribed after a person has tested positive for COVID-19 and within 5 days of symptom onset. Talk to a provider about your eligibility for antiviral treatment.

What Are Monoclonal Antibody Therapies?

Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on cells. Monoclonal antibodies are designed to block viral attachment and entry into human cells, thus neutralizing the virus. It is designed to limit viral replication and may be effective for the treatment of COVID-19 in patients who are at high risk for progressing to severe COVID-19 and/or hospitalization.

Monoclonal antibody treatment is for people who have tested positive for COVID-19 and have mild to moderate symptoms. When administered to non-hospitalized patients as soon as possible after positive viral testing for SARS-CoV-2 and within 7 days of symptom onset, monoclonal antibodies may reduce viral load, symptoms, and risk of hospitalizations and emergency room visits associated with COVID-19. Information reported by the manufacturers to the food and drug administration indicates that among high-risk symptomatic individuals, there is a 70% reduction in hospitalizations and deaths.

Bebtelovimab is currently the only authorized monoclonal antibody therapy given the prevalence of the Omicron BA.2 sub-variant.